A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Enrolling by invitation · NCT05872022
Conditions: Pregnancy, Obesity, Overweight
At a glance
- Research payments reported, 2025
- $500
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 728
About the trial
- Sponsor
- Novo Nordisk A/S
- Tested
- No Intervention (other)
- Dates
- Started 2023-07-05; completion 2032-12-30
- Results posted
- Not yet
This is an observational, prospective Wegovy (semaglutide 2.4 milligram \[mg\]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with ac…
From ClinicalTrials.gov, last updated 2026-01-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Novo Nordisk As reported $500 in research payments for this study in 2025 (4 payments).
Products named: Wegovy
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Holly A. Hoenes, M.D. Pediatrics · Forsyth, GA
- Lisa S. Vernon, M.D. OB-GYN (Obstetrics & Gynecology) · Manahawkin, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $250
- Lisa Vernon, MD, Facog, LLC $150
- Northside Pediatrics, PC $100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.